No connection

Search Results

AKTS vs KMTS

AKTS
Aktis Oncology, Inc.
BEARISH
Price
$18.99
Market Cap
$1.05B
Sector
Healthcare
AI Confidence
85%
KMTS
Kestra Medical Technologies, Ltd.
BEARISH
Price
$17.87
Market Cap
$1.04B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
AKTS
--
KMTS
--
Forward P/E
AKTS
-11.02
KMTS
-8.35
P/B Ratio
AKTS
-0.12
KMTS
3.62
P/S Ratio
AKTS
188.43
KMTS
12.46
EV/EBITDA
AKTS
-0.9
KMTS
-5.9

Profitability

Gross Margin
AKTS
0.0%
KMTS
48.75%
Operating Margin
AKTS
-1675.78%
KMTS
-141.6%
Profit Margin
AKTS
0.0%
KMTS
-172.99%
ROE
AKTS
-26.5%
KMTS
-92.65%
ROA
AKTS
-14.8%
KMTS
-36.84%

Growth

Revenue Growth
AKTS
--
KMTS
62.7%
Earnings Growth
AKTS
--
KMTS
--

Financial Health

Debt/Equity
AKTS
0.05
KMTS
0.16
Current Ratio
AKTS
9.27
KMTS
7.32
Quick Ratio
AKTS
9.18
KMTS
7.08

Dividends

Dividend Yield
AKTS
--
KMTS
--
Payout Ratio
AKTS
0.0%
KMTS
0.0%

AI Verdict

AKTS BEARISH

AKTS exhibits weak financial health per the Piotroski F-Score of 3/9, indicating significant operational and profitability concerns, with negative margins, ROE, and ROA. The absence of an Altman Z-Score raises distress risk concerns, particularly given the company's negative earnings and extreme operating losses. Despite a strong analyst consensus of 'strong_buy' and a high target price, the stock trades at an inflated Price/Sales of 188.43 and lacks any intrinsic value anchor. The recent earnings surprises are volatile and predominantly negative, with a 101.51% average miss over the last four quarters, undermining credibility. The 15.2% decline across all time horizons further reflects persistent market skepticism.

Strengths
Analyst consensus is strongly bullish with a 'strong_buy' rating and a target price of $31.25, implying significant upside potential
Recent quarterly EPS growth shows strong momentum (+94.7% Q/Q, +85.2% YoY), suggesting improving earnings trajectory
Insider sentiment is moderately positive at 60/100, indicating some confidence among insiders despite no recent trades
Risks
Piotroski F-Score of 3/9 indicates poor financial health, with negative profitability, declining margins, and weak return metrics
No Altman Z-Score available, but the extreme operating margin (-1675.78%) and negative ROE (-26.50%) suggest high distress risk
Price/Sales of 188.43 is astronomically high, indicating the stock is priced for perfection and highly sensitive to growth disappointment
KMTS BEARISH

KMTS exhibits severe fundamental weakness, highlighted by a critical Piotroski F-Score of 1/9, indicating poor operational health and financial instability. Despite strong top-line revenue growth of 62.7% and a high current ratio of 7.32, the company suffers from deep negative profit margins (-172.99%) and a complete lack of positive earnings. The disconnect between the 'Strong Buy' analyst consensus and the actual technical trend (0/100) and bearish insider selling suggests a significant valuation bubble or over-optimism regarding future scaling.

Strengths
Strong YoY revenue growth of 62.70%
Excellent short-term liquidity (Current Ratio 7.32)
Healthy Gross Margin of 48.75% suggesting product viability
Risks
Critical operational failure indicated by Piotroski F-Score of 1/9
Severe negative profitability (Profit Margin -172.99%)
Strong bearish technical trend with consistent price declines

Compare Another Pair

AKTS vs KMTS: Head-to-Head Comparison

This page compares Aktis Oncology, Inc. (AKTS) and Kestra Medical Technologies, Ltd. (KMTS) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile